An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Status:	Recruiting
Healthy:	No
Age Range:	18 - Any
Updated:	2/3/2019
Start Date:	June 20, 2016
End Date:	September 19, 2022
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email:	Clinical.Trials@bms.com

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

The purpose of this study is to assess the safety and tumor-shrinking ability of experimental
medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers
that are advanced or have spread.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Men and women at least 18 years of age

- Advanced solid tumors

- Eastern Cooperative Oncology Group (ECOG) 0-1

- Acceptable lab testing results

- Allow biopsies

Exclusion Criteria:

- Central nervous system (CNS) tumors

- Uncontrolled or significant cardiovascular diseases

- Active or known autoimmune disease

- Organ transplant

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

The Kinghorn Cancer Centre

370 Victoria Street
Darlinghurst, New South Wales 2010

Phone: +61293555783

from

Darlinghurst,